Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Accepts Supplemental New Drug Application for Priority Review of Rapamune (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
FDA Accepts Supplemental New Drug Application for Priority Review of Rapamune (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
FDA Accepts Supplemental New Drug Application for Priority Review of Rapamune (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
Submitted by
admin
on February 21, 2015 - 9:59am
Source:
Yahoo/BusinessWire
News Tags:
Lymphangioleiomyomatosis
Rapamune
Headline:
FDA Accepts Supplemental New Drug Application for Priority Review of Rapamune (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)
Do Not Allow Advertisers to Use My Personal information
